Group 1 - Tecan Group successfully raised CHF 150 million through the issuance of a fixed rate domestic straight bond with a coupon of 0.850% and a duration of 5 years [1][2] - The net proceeds from the bond issuance will be used for general corporate purposes, including the repayment of an outstanding CHF 250 million bond maturing in October 2025 [2] - The bonds were placed with institutional investors and private banks in Switzerland, managed by UBS Investment Bank and Zürcher Kantonalbank, with Bank J. Safra Sarasin as Co-Lead Manager [2] Group 2 - Tecan is a global leader in laboratory automation, improving healthcare innovation from life science to clinical applications [3] - Founded in Switzerland in 1980, Tecan has over 3,000 employees and operates manufacturing, research, and development sites in Europe, North America, and Asia [3] - In 2024, Tecan generated sales of CHF 934 million (USD 1,062 million; EUR 984 million) [3]

Core Insights - Tecan reported solid financial results for the first half of 2025, confirming its outlook for the full year despite ongoing market challenges [1][2] Financial Performance - Order entry for H1 2025 was CHF 458.3 million, a decrease of 2.9% year-on-year, but showed sequential improvement with mid-single-digit growth in Q2 [3] - Sales decreased by 5.9% in Swiss francs to CHF 439.5 million, with a decline of 3.7% in local currencies; however, there was a sequential improvement from Q1 to Q2 [4][5] - Adjusted EBITDA was CHF 65.7 million, with an improved margin of 15.0% despite lower sales volume [6] - Adjusted net profit was CHF 33.7 million, down from CHF 36.5 million in H1 2024, impacted by foreign exchange effects and a higher effective tax rate [7] Business Segment Analysis - Life Sciences Business sales were CHF 185.7 million, a slight decrease of 1.0% in Swiss francs but an increase of 1.6% in local currencies, supported by growth in clinical diagnostics [9][10] - Partnering Business sales were CHF 253.8 million, down 9.2% in Swiss francs, with strong growth in in-vitro diagnostics systems but a decline in Cavro OEM components [12][13] Operational Highlights - Tecan enhanced operational resilience through cost-reduction programs and site consolidations, including the closure of two California sites [16][17] - Continued focus on innovation with new product launches such as Veya™ and FlowPilot, aimed at improving laboratory workflows [19][20] Share Buyback Program - Tecan announced a share buyback program of up to CHF 120 million, reflecting confidence in long-term growth prospects [26][27] Outlook for 2025 - Tecan confirmed its full-year sales outlook, expecting sales in local currencies to range from a low single-digit percentage decline to low single-digit percentage growth [29] - The company anticipates an adjusted EBITDA margin of 17.5% to 18.5% for the full year [30]

Core Viewpoint - Tecan Group is undergoing a CEO transition, with Dr. Achim von Leoprechting stepping down after nearly 12 years, and Monica Manotas appointed as the new CEO effective August 1, 2025, marking a significant leadership change in the company's growth trajectory [1][3][6]. Company Leadership Transition - Dr. Achim von Leoprechting will remain with Tecan in an advisory role to ensure a smooth transition [2]. - Monica Manotas, who has been on the Board since April 2024, will take over as CEO, bringing over 20 years of international experience in the life sciences industry, particularly from her tenure at Thermo Fisher Scientific [3][8]. - The transition will involve close cooperation between Dr. von Leoprechting and Ms. Manotas to ensure a diligent handover [3]. Financial Outlook - Tecan is set to publish its financial results for the first half of 2025 on August 12, 2025, and anticipates a mid-single-digit percentage decline in sales in local currencies for that period [4]. - The company confirms its outlook for 2025 and mid-term projections as previously communicated [4]. Company Performance and Strategy - Under Dr. von Leoprechting's leadership, Tecan has experienced a 60% growth since 2018, driven by organic growth and acquisitions, while maintaining solid EBITDA margins and strong cash flow [5]. - The company has focused on strengthening innovation capabilities and expanding into key application areas such as research, pharma, and clinical diagnostics, as well as the medical market [5]. - Tecan is well-positioned for future growth, with Monica Manotas expected to lead the company into its next phase, leveraging her deep understanding of the market [6][7]. Company Background - Tecan, founded in Switzerland in 1980, is a leader in laboratory automation and develops OEM instruments and medical devices, with over 3,000 employees and a global presence in more than 70 countries [10]. - In 2024, Tecan generated sales of CHF 934 million (approximately USD 1,062 million) [10].

Core Viewpoint - Tecan Group reports performance in line with expectations for Q1 2025 and confirms its sales outlook for the full year, anticipating a range of low single-digit percentage decline to low single-digit percentage growth in local currencies [1][6]. Sales Performance - Sales in local currencies for Q1 2025 declined within a mid-single-digit percentage range, with the Life Sciences Business segment performing solidly, close to prior-year levels, driven by increased sales in clinical diagnostics, particularly genomic testing [2][4]. - The Partnering Business segment experienced a slightly larger decline, attributed to the timing of customer orders, with expectations for higher sales volumes in the second half of the year [3]. Market Conditions - Sales to US academic and governmental accounts are affected by uncertainty regarding funding releases, while the market in China is stabilizing, with a projected single-digit decline for the full year [4]. - Early signs of recovery are noted in sales to biopharma customers, with a more significant revenue impact expected in the latter half of the year [5]. Financial Outlook - Tecan confirms its full-year 2025 sales outlook, expecting local currency sales to range from a low single-digit percentage decline to low single-digit percentage growth, alongside an adjusted EBITDA margin forecast of 17.5% to 18.5% [6]. - The company anticipates returning to average organic growth rates in the mid to high single-digit percentage range under normal market conditions [7]. Tariff Impact - The potential impact of US reciprocal tariffs is assessed as limited, with approximately 50% of US revenues generated from localized operations. Estimated EBITDA impact ranges from mid- to high-single-digit million Swiss francs if higher tariffs take effect [8][9]. Product Innovation - Tecan launched the Veya™ multi-omics liquid handling workstation in January 2025, receiving strong interest and positive feedback [12]. - The company expanded its specialty diagnostics offering through acquisitions and partnerships, including a collaboration with Grifols for biomarker panels [13][14]. Strategic Partnerships - Tecan secured a manufacturing contract for a major diagnostic system and expanded relationships with life science research customers, enhancing its project pipeline across various segments [14]. Key Dates - The adjusted EBITDA expectations are based on an average exchange rate forecast for 2025, with one euro equaling CHF 0.95 and one US dollar equaling CHF 0.90 [15].